e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15(7); 409-414

Original Research Article

Evaluation of the Effect of Iron Sucrose and Ferrous Ascorbate for the Treatment of Anaemia during Pregnancy: A Randomised Controlled Trial

Ritvija Dixit[1], Adreena Mittal[2], Parul Singhal[3], Saborni Dey[4]

[1]Assistant Professor, Department of Physiology, Saraswathi Institute of Medical Sciences and Hospital, Hapur, Uttar Pradesh, India.
[2]Associate Professor, Department of Pathology, Saraswathi Institute of Medical Sciences and Hospital, Hapur, Uttar Pradesh, India.
[3]Professor, Department of Pathology, Saraswathi Institute of Medical Sciences and Hospital, Hapur, Uttar Pradesh, India.
[4]Professor, Department of Pharmacology, Saraswathi Institute of Medical Sciences and Hospital, Hapur, Uttar Pradesh, India.

Received: 20-03-2023 / Revised: 21-04-2023 / Accepted: 25-05-2023
Corresponding author: Dr. Ritvija Dixit
Conflict of interest: Nil

Abstract:

Background: Anaemia during pregnancy is a prevalent condition associated with adverse maternal and fetal outcomes. Traditional oral iron supplementation often faces challenges in terms of efficacy, tolerability, and compliance. This study aimed to evaluate the effectiveness of alternative iron formulations, iron sucrose and ferrous ascorbate, in treating anaemia during pregnancy through a randomized controlled trial.

Methods: A total of 400 pregnant women with anaemia were randomized into four treatment groups: iron sucrose, ferrous ascorbate, traditional oral iron, and placebo. The primary outcomes assessed were changes in hemoglobin levels and the proportion of participants achieving target hemoglobin levels. Secondary outcomes included adverse effects, pregnancy outcomes, quality of life, compliance rates, and patient satisfaction.

Results: Both iron sucrose and ferrous ascorbate demonstrated significant improvements in hemoglobin levels compared to traditional oral iron and placebo ($p < 0.001$). The proportion of participants achieving target hemoglobin levels was higher in the iron sucrose and ferrous ascorbate groups ($p < 0.001$). Adverse effects were generally mild, with no significant differences between the treatment groups ($p = 0.052$). The iron sucrose and ferrous ascorbate groups showed lower incidences of preterm birth and low birth weight ($p < 0.05$) and higher quality of life scores ($p < 0.001$). Compliance rates were high across all groups, with the highest satisfaction reported in the iron sucrose and ferrous ascorbate groups ($p < 0.001$).

Conclusion: Iron sucrose and ferrous ascorbate demonstrated superior efficacy in improving hemoglobin levels and achieving target hemoglobin levels compared to traditional oral iron and placebo. These alternative iron formulations also showed favorable safety profiles and positive impacts on pregnancy outcomes, quality of life, compliance, and patient satisfaction. These findings support the consideration of iron sucrose and ferrous ascorbate as potential alternatives for the management of anaemia during pregnancy, providing better options for pregnant women and their offspring.

Keywords: anaemia, pregnancy, iron sucrose, ferrous ascorbate, randomized controlled trial.

Introduction

Anaemia during pregnancy is a significant health concern affecting a substantial number of women worldwide. It is characterized by a decrease in red blood cell count or hemoglobin levels, leading to reduced oxygen-carrying capacity in the blood. Maternal anaemia not only poses risks to the mother's health but also has profound implications for fetal development and overall pregnancy outcomes.[1,2]Iron deficiency is the most common cause of anaemia during pregnancy. Adequate iron supplementation is crucial to restore hemoglobin levels and prevent the adverse effects associated with anaemia. Traditional oral iron formulations have been widely used for treating this condition.

However, their effectiveness is often hindered by poor tolerability, gastrointestinal side effects, and low compliance rates among pregnant women.[1,3]

In recent years, alternative iron formulations such as iron sucrose and ferrous ascorbate have gained attention as potential alternatives for managing anaemia during pregnancy. Iron sucrose is an intravenous iron formulation that provides a rapid and direct delivery of iron into the bloodstream, bypassing the gastrointestinal tract. Ferrous ascorbate, on the other hand, is an oral iron preparation that combines iron with ascorbic acid, enhancing iron absorption and minimizing adverse effects.[3-8]

Given the potential benefits of these alternative iron formulations, it is essential to evaluate their efficacy and safety in treating anaemia during pregnancy. Randomized controlled trials (RCTs) serve as the gold standard for assessing the effectiveness of medical interventions, allowing for rigorous comparisons between treatment options and placebo controls.

This study aims to conduct a randomized controlled trial to evaluate the effect of iron sucrose and ferrous ascorbate for the treatment of anaemia during pregnancy. By comparing these alternative iron formulations with traditional oral iron supplementation and placebo, we can comprehensively assess their impact on improving maternal hemoglobin levels, reducing anaemia-related symptoms, and enhancing pregnancy outcomes.

The findings from this randomized controlled trial will provide valuable insights into the comparative efficacy and safety of iron sucrose and ferrous ascorbate in treating anaemia during pregnancy. This research has the potential to inform clinical practice guidelines and improve the management of anaemia, ultimately benefiting the health and well-being of pregnant women and their offspring.

Study Objectives

The primary objectives of this trial include determining the change in hemoglobin levels, assessing the proportion of women achieving target hemoglobin levels, evaluating adverse effects and tolerability, and monitoring pregnancy outcomes such as preterm birth, low birth weight, and perinatal mortality. Secondary endpoints will include quality of life measures, compliance rates, and patient satisfaction.

Materials and Methods

Study Design

This study employed a randomized controlled trial design to evaluate the effect of iron sucrose and ferrous ascorbate for the treatment of anaemia during pregnancy. The trial adhered to ethical guidelines.

Study Participants

A total of 400 pregnant women diagnosed with anaemia were recruited from antenatal clinics or healthcare facilities. Inclusion criteria included gestational age between 12 and 30 weeks, confirmed diagnosis of anaemia based on hemoglobin levels below a specified threshold, and willingness to participate in the study. Exclusion criteria encompassed pre-existing conditions that could confound the study outcomes or affect iron absorption, such as hemoglobinopathies or chronic diseases.

Randomization

Participants meeting the eligibility criteria were randomly assigned to one of the four study groups using computer-generated randomization tables. The allocation ratio was 1:1:1:1, ensuring equal representation in each group. Allocation concealment was ensured to maintain blinding.

Interventions

The study involved four treatment arms:

a) **Iron sucrose group**: Participants received intravenous iron sucrose at a prescribed dose and frequency.
b) **Ferrous ascorbate group:** Participants received oral ferrous ascorbate at a prescribed dose and frequency.
c) **Traditional oral iron group**: Participants received traditional oral iron supplementation, following standard clinical practice guidelines.
d) **Placebo group:** Participants received a placebo intervention that mimicked the appearance and administration method of the active treatments.

Dosing and Monitoring

The dosing regimen for each intervention group was predetermined based on established guidelines or literature evidence. Compliance with the assigned treatment was monitored through regular follow-up visits, participant self-reporting, and medication reconciliation.

Outcome Measures

Primary outcome measures included changes in hemoglobin levels from baseline to specific time points during the study, the proportion of participants achieving target hemoglobin levels, and adverse effects/tolerability of the interventions. Secondary outcome measures encompassed pregnancy outcomes (e.g., preterm birth, low birth weight, perinatal mortality), quality of life assessments, compliance rates, and patient satisfaction.

Sample Size Calculation

The sample size calculation was based on the expected effect size, statistical power, significance level, and anticipated dropout rate. Considering a 5% significance level, 80% power, and an effect size of 0.5, the sample size was determined to be 100 participants per group, totaling 400 participants. This sample size was deemed sufficient to detect clinically significant differences in the primary outcome measures between the study groups.

Data Collection and Analysis

Data on demographic characteristics, medical history, and study outcomes were collected using standardized data collection forms. Statistical analysis was performed using appropriate tests such as chi-square test, t-test, or analysis of variance (ANOVA), depending on the nature of the data.

Subgroup analyses and regression models were utilized to explore potential confounding factors or effect modifiers.

Ethical Considerations

The trial adhered to ethical principles, including informed consent procedures, protection of participants' privacy and confidentiality, and data handling in accordance with applicable regulations. Any potential risks or adverse events associated with the interventions were closely monitored and promptly reported.

Results

In this study, a total of 400 pregnant women with anaemia were enrolled and randomized into four treatment groups: iron sucrose, ferrous ascorbate, traditional oral iron, and placebo. Table 1 presents the baseline characteristics of the study participants, indicating comparable demographics across the groups ($p > 0.05$).

Table 1: Baseline Characteristics of Study Participants

Characteristic	Iron Sucrose Group	Ferrous Ascorbate Group	Traditional Oral Iron Group	Placebo Group
Number of Participants	100	100	100	100
Age (years), mean (SD)	28.5 (3.2)	29.1 (2.8)	28.8 (3.5)	28.9 (3.1)
Gestational Age (weeks), mean (SD)	20.3 (2.1)	20.2 (2.3)	20.1 (2.0)	20.0 (2.2)
Hemoglobin Level (g/dL), mean (SD)	9.8 (0.9)	9.7 (0.8)	9.6 (0.7)	9.5 (0.9)

The primary outcome measures, as shown in Table 2, demonstrate the efficacy of the interventions in improving hemoglobin levels. The iron sucrose group and ferrous ascorbate group achieved higher increases in hemoglobin levels compared to the traditional oral iron group and placebo group ($p < 0.001$).

Furthermore, a higher proportion of participants in the iron sucrose and ferrous ascorbate groups achieved the target hemoglobin levels compared to the other two groups ($p < 0.001$). Adverse effects were generally mild and similar across the treatment groups, with the lowest incidence observed in the placebo group ($p = 0.052$).

Table 2: Primary Outcome Measures

Outcome Measure	Iron Sucrose Group	Ferrous Ascorbate Group	Traditional Oral Iron Group	Placebo Group
Change in Hemoglobin Levels (g/dL)	2.3 (0.7)	2.2 (0.6)	1.9 (0.5)	0.3 (0.2)
Proportion Achieving Target Hemoglobin Levels (%)	82.0	80.0	76.0	12.0

Adverse Effects (%)	10.0	8.0	12.0	4.0

Table 3 presents the secondary outcome measures. The incidence of preterm birth and low birth weight was lower in the iron sucrose and ferrous ascorbate groups compared to the traditional oral iron group and placebo group ($p < 0.05$). Perinatal mortality rates were low in all groups, with no significant differences observed ($p = 0.764$). Participants in the iron sucrose and ferrous ascorbate groups reported higher quality of life scores compared to the traditional oral iron group and placebo group ($p < 0.001$). Compliance rates were high in all groups, with the highest compliance seen in the placebo group ($p = 0.209$). Patient satisfaction scores were generally positive across all groups, with slightly higher scores reported in the iron sucrose and ferrous ascorbate groups ($p < 0.001$).

Table 3: Secondary Outcome Measures

Outcome Measure	Iron Sucrose Group	Ferrous Ascorbate Group	Traditional Oral Iron Group	Placebo Group
Preterm Birth (%)	8.0	7.0	10.0	12.0
Low Birth Weight (%)	6.0	5.0	8.0	10.0
Perinatal Mortality (%)	1.0	1.0	2.0	2.0
Quality of Life (mean score, SD)	7.2 (0.9)	7.4 (0.8)	7.0 (1.0)	6.8 (0.7)
Compliance Rate (%)	93.0	92.0	89.0	95.0
Patient Satisfaction (mean score, SD)	8.5 (1.2)	8.6 (1.1)	8.3 (1.3)	7.9 (1.0)

Note: Values are presented as mean (SD) or percentages (%). p-values < 0.05 are considered statistically significant. Overall, the results of this study suggest that both iron sucrose and ferrous ascorbate are effective in improving hemoglobin levels and achieving target hemoglobin levels in pregnant women with anaemia ($p < 0.001$). These alternative iron formulations also demonstrated favorable effects on pregnancy outcomes, quality of life, compliance, and patient satisfaction compared to traditional oral iron supplementation and placebo.

Discussion

The present study aimed to evaluate the effect of iron sucrose and ferrous ascorbate for the treatment of anaemia during pregnancy through a randomized controlled trial. The results demonstrated significant improvements in hemoglobin levels and achievement of target hemoglobin levels in both the iron sucrose and ferrous ascorbate groups compared to the traditional oral iron group and placebo. These findings highlight the potential efficacy of alternative iron formulations in managing anaemia during pregnancy, addressing the limitations of traditional oral iron supplementation.

The observed increase in hemoglobin levels in the iron sucrose and ferrous ascorbate groups supports their effectiveness in correcting iron deficiency and improving maternal erythropoiesis. The direct delivery of iron into the bloodstream through intravenous administration of iron sucrose bypasses the gastrointestinal tract, potentially enhancing iron absorption and minimizing gastrointestinal side effects. Similarly, the combination of iron with ascorbic acid in ferrous ascorbate aids in iron absorption and reduces adverse effects associated with oral iron supplementation. The superiority of these alternative iron formulations over traditional oral iron in improving hemoglobin levels is consistent with previous studies.[5-10]

Achieving target hemoglobin levels is crucial in managing anaemia during pregnancy as it indicates successful replenishment of iron stores and restoration of oxygen-carrying capacity. The higher proportion of participants achieving target hemoglobin levels in the iron sucrose and ferrous ascorbate groups further emphasizes their efficacy. This finding suggests that alternative iron formulations may offer better treatment outcomes and reduce the risk of persistent or refractory anaemia during pregnancy.

In terms of safety and tolerability, the incidence of adverse effects was generally low across all groups. The observed mild adverse effects in the iron sucrose and ferrous ascorbate groups were within an acceptable range and consistent with previous studies.[7-12] The low incidence of adverse effects in the placebo group confirms the absence of significant placebo-related effects. These findings

support the safety profile of iron sucrose and ferrous ascorbate, making them viable options for pregnant women with anaemia.

Secondary outcome measures, including pregnancy outcomes, quality of life, compliance rates, and patient satisfaction, provide additional insights into the impact of alternative iron formulations. The lower incidence of preterm birth and low birth weight in the iron sucrose and ferrous ascorbate groups suggests their potential benefits in improving fetal growth and reducing adverse pregnancy outcomes associated with anaemia.[7,13,14,15] The higher quality of life scores reported in these groups indicate improved overall well-being and reduced anaemia-related symptoms.

Compliance rates were generally high in all groups, emphasizing the acceptability and feasibility of the interventions. The higher compliance rate observed in the placebo group may be attributed to the absence of adverse effects commonly associated with iron supplementation. Patient satisfaction scores were also higher in the iron sucrose and ferrous ascorbate groups, indicating a positive perception of these alternative iron formulations among pregnant women.[16-18]

Comparison with other studies[19-22]reveals consistent findings regarding the efficacy and safety of iron sucrose and ferrous ascorbate.

Limitations:

Potential limitations of the study include the inherent challenges in blinding participants and investigators due to the different administration methods of the interventions. Additionally, participant compliance and adherence to the assigned treatments may vary, potentially influencing the results.

Conclusion

In conclusion, the results of this randomized controlled trial provide evidence supporting the efficacy and safety of iron sucrose and ferrous ascorbate in the treatment of anaemia during pregnancy. Both alternative iron formulations demonstrated superior effectiveness in improving hemoglobin levels, achieving target hemoglobin levels, and influencing pregnancy outcomes compared to traditional oral iron supplementation and placebo. The observed benefits, along with their favorable tolerability and patient satisfaction, suggest that iron sucrose and ferrous ascorbate can be considered as potential alternatives for the management of anaemia during pregnancy.

References

1. Abu-Ouf NM, Jan MM. The impact of maternal iron deficiency and iron deficiency anemia on child's health. Saudi Med J. 2015 Feb;36(2):146-9.
2. Stephen G, Mgongo M, Hussein Hashim T, Katanga J, Stray-Pedersen B, Msuya SE. Anaemia in Pregnancy: Prevalence, Risk Factors, and Adverse Perinatal Outcomes in Northern Tanzania. Anemia. 2018 May 2; 2018:1846280.
3. Means RT. Iron Deficiency and Iron Deficiency Anemia: Implications and Impact in Pregnancy, Fetal Development, and Early Childhood Parameters. Nutrients. 2020 Feb 11;12(2):447.
4. Neeru S, Nair NS, Rai L. Iron sucrose versus oral iron therapy in pregnancy anemia. Indian J Community Med. 2012 Oct;37(4):214-8.
5. Kriplani A, Mahey R, Dash BB, Kulshreshta V, Agarwal N, Bhatla N. Intravenous iron sucrose therapy for moderate to severe anaemia in pregnancy. Indian J Med Res. 2013;138(1):78-82.
6. Santra A, Sharma K, Singh N, et al. (February 25, 2023) Role of Intravenous Iron Sucrose in Severe Anemia in Late Pregnancy: A Case Report From Rural Ballabgarh, Haryana. Cureus 15(2): e35472.
7. Thobbi VA, Bijapur ZNM.A comparative study of efficacy, safety and compliance of oral iron versus intravenous iron sucrose in treatment of iron deficiency anaemia of pregnancy.Int J Reprod Contracept Obstet Gynecol2020;9:3852-7.
8. Khatun F, Biswas C.Comparative study of intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy. Int J Reprod Contracept Obstet Gynecol 2022; 11:505-12.
9. Haldar P, Kant S, Yadav V, Majhi J, Malhotra S, Kaur R, Kumar R, Singh AK, Archana S, Lohia A, Rath R, Ahamed F. Effect of intravenous iron sucrose on hemoglobin level, when administered in a standard-dose, to anemic pregnant women in rural Northern India. J

Family Med Prim Care. 2018 Jul-Aug;7(4):762-768.
10. Cançado RD, de Figueiredo PO, Olivato MC, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Rev Bras Hematol Hemoter. 2011;33(6):439-43.
11. Cançado RD, de Figueiredo PO, Olivato MC, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Rev Bras Hematol Hemoter. 2011;33(6):439-43.
12. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ, Lee IS. Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients. Curr Med Res Opin. 2013 Feb;29(2):141-7.
13. Benson CS, Shah A, Frise MC, Frise CJ. Iron deficiency anaemia in pregnancy: A contemporary review. Obstet Med. 2021 Jun;14(2):67-76.
14. Tandon, Rimpy et al. "Management of Iron Deficiency Anemia in Pregnancy in India." Indian journal of hematology & blood transfusion: an official journal of Indian Society of Hematology and Blood Transfusion vol. 34,2 (2018): 204-215.
15. Macher S, Herster C, Holter M, Moritz M, Matzhold EM, Stojakovic T, et al. The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT. Nutrients. 2020;12(5):1313.
16. Mithra, P et al. "Compliance with iron-folic acid (IFA) therapy among pregnant women in an urban area of south India." African health sciences vol. 13,4 (2013): 880-5.
17. Silitonga, Hanna Tabita Hasianna et al. "Com pliance of Iron Supplementation and Determinants among Adolescent Girls: A Systematic Review." Iranian journal of public health vol. 52,1 (2023): 37-48.
18. Kamau, M.W., Mirie, W. & Kimani, S. Compliance with Iron and folic acid supplementation (IFAS) and associated factors among pregnant women: results from a cross-sectional study in Kiambu County, Kenya. BMC Public Health.2018; 18:580.
19. Patil KA, Tehalia MK. Comparative efficacy and safety of ferric carboxymaltose, iron sucrose and iron sorbitol in treatment of iron deficiency anemia in Indian pregnant women.Int J Reprod Contracept Obstet Gynecol 2022;11:2692-8.
20. Gupta, Avantika et al. "A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy." Indian journal of hematology & blood transfusion: an official journal of Indian Society of Hematology and Blood Transfusion vol. 30,2 (2014): 120-5.
21. Chavan S, Rana P, Tripathi R, Tekur U. Comparison of efficacy & safety of iron polymaltose complex & ferrous ascorbate with ferrous sulphate in pregnant women with iron-deficiency anaemia. Indian J Med Res. 2021 Jul;154(1):78-84.
22. Malhotra N, Kriplani A, Pal B, et al. Ferrous Ascorbate: Current Clinical Place of Therapy in the Management of Iron Deficiency Anemia. J South Asian Feder Obst Gynae 2021; 13(3):103–109